First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients

First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients

Enfortumab vedotin (EV), an antibody–drug conjugate directed against Nectin-4, significantly prolonged survival compared to standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma who previously received platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. Th...

Full description

Bibliographic Details
Main Authors: Christof Vulsteke, Laurens De Cocker, Alfonso Gómez de Liaño, Cristina Montesdeoca, Astrid De Meulenaere, Lieselot Croes, Danielle Delombaerde, Bernadett Szabados, Thomas Powles
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Pharmaceuticals
Subjects:
enfortumab vedotin
brain metastases
antibody–drug conjugate
Online Access:https://www.mdpi.com/1424-8247/16/3/375

Similar Items

Similar Items